Influence of diabetes mellitus on the clinical course of community-acquired pneumonia
| Diabetes patients | Nondiabetes patients | p-value# | |
| Patients | 12.3 (162) | 87.7 (1156) | |
| Clinical course days median (IQR) | |||
| LOS¶ | 6 (4–10) | 5 (3–8) | <0.001 |
| LOAB | 10 (8–12) | 10 (8–12) | 0.87 |
| LOIVAB | 4 (2–7) | 3 (2–6) | 0.01 |
| Severe outcome | |||
| ICU admittance | 13.0 (21) | 9.2 (106) | 0.13 |
| In-hospital mortality | 10.5 (17) | 8.1 (94) | 0.31 |
| Any severe event+ | 19.8 (32) | 13.9 (161) | 0.05 |
Data are presented as % (n), unless otherwise stated. Missing information for length of antibiotic treatment (LOAB) and intravenous antibiotic treatment (LOIVAB) were 34 (2.5%) and 12 (0.9%) patients, respectively. IQR: interquartile range; LOS: length of stay; ICU: intensive care unit. #: LOS, use of antibiotics, need for ICU support and mortality were assessed in a univariate analysis stratified by diabetes; ¶: patients who died in hospital were counted as missing data (n=111, 8.4%); +: in-hospital mortality and/or ICU admission.